<DOC>
	<DOCNO>NCT01725113</DOCNO>
	<brief_summary>The purpose non-inferiority study compare safety effectiveness mineral bone disease treatment protocol base calcitriol one base paricalcitol hemodialysis patient use revise Kidney Disease : Improving Global Outcomes ( KDIGO ) parathyroid hormone target .</brief_summary>
	<brief_title>Management Mineral Bone Disease Hemodialysis-Calcitriol vs. Paricalcitol</brief_title>
	<detailed_description>Active vitamin D analog mainstay treatment patient hemodialysis mineral bone disease ( MBD ) past decade . Intravenous calcitriol active vitamin D analog nearly identical natural 1 , 25 Vitamin D3 . Calcitriol result hydroxylation previtamin D3 liver kidney . Paricalcitol , 19-nor-1 , 25-dihydroxyvitamin D2 , new agent vitamin D analog . This agent believe effect specific parathyroid gland , less specific absorption calcium phosphorus gut . Although formulation appear equally effective suppress parathyroid hormone ( PTH ) , study suggest great calcemic effect intravenous calcitriol compare paricalcitol ( 1 ) . Due , paricalcitol predominant active vitamin D analog use hemodialysis patient United States . Two recent change management hemodialysis patient likely reduce amount active vitamin D analog use near future : liberalization PTH goal accord international guideline , ( 2 ) implementation bundle payment dialysis Medicare . These change challenge previous study analyze safety efficacy medication . The purpose prospective , randomize , cross-over study determine whether calcitriol safe effective paricalcitol treatment MBD hemodialysis patient use revise KDIGO parathyroid hormone target . Our hypothesis calcitriol equally safe effective paricalcitol treatment MBD hemodialysis patient .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>All subject treat least three month hemodialysis IV paricalcitol . These subject must recent calcium level within normal range , recent phosphorus level &lt; 8 mg/dL recent PTH 130585 pg/mL Patients exclude : 1. age great 18 2. active malignancy 3. expect survival great 6 month 4. high likelihood renal transplant study period . 5 . Low calcium bath 6. prior parathyroidectomy 7. use calcimimetics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>